AR and neoplasm: We further hypothesized that tumor cell expression of AKR1C3 and constitutively active AR variants could be of relevance for individual tumor response to 2nd line ADT and clinical progression [8], and the 28 bone metastases evaluated for both AKR1C3 and AR-V expression were therefore divided according to their AR-V and AKR1C3 protein expression levels, as shown in Figure 5, in order to demonstrate sub-groups of possible clinical relevance.